{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"19"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"11"},{"groupId":"OG005","value":"16"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"9"},{"groupId":"OG008","value":"9"}]}],"title":"Non-Responder"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"}]}],"title":"Responder"}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"13"},{"groupId":"OG005","value":"20"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"9"},{"groupId":"OG008","value":"9"},{"groupId":"OG009","value":"0"}],"units":"Participants"}],"description":"Response rates will be calculated as the percent of patients whose best response is a Complete Response (CR) or Partial Response (PR).","groups":[{"description":"Group 1 - Recurrent or Refractory Hepatoblastoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.\n\ncixutumumab: Given IV\n\nlaboratory biomarker analysis: Correlative studies","id":"OG000","title":"Group 1 - Recurrent or Refractory Hepatoblastoma"},{"description":"Group 2 - Recurrent or Refractory Synovial Sarcoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.\n\ncixutumumab: Given IV\n\nlaboratory biomarker analysis: Correlative studies","id":"OG001","title":"Group 2 - Recurrent or Refractory Synovial Sarcoma"},{"description":"Group 3 - Recurrent or Refractory Rhabdomyosarcoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.\n\ncixutumumab: Given IV\n\nlaboratory biomarker analysis: Correlative studies","id":"OG002","title":"Group 3 - Recurrent or Refractory Rhabdomyosarcoma"},{"description":"Group 4 - Recurrent or Refractory Adrenocortical Carcinoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.\n\ncixutumumab: Given IV\n\nlaboratory biomarker analysis: Correlative studies","id":"OG003","title":"Grp 4-Recurrent or Refractory Adrenocortical Carcinoma"},{"description":"Group 5 - Recurrent or Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.\n\ncixutumumab: Given IV\n\nlaboratory biomarker analysis: Correlative studies","id":"OG004","title":"Grp 5-Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor"},{"description":"Group 6 - Recurrent or Refractory Neuroblastoma -MIBG Positive Without Measurable Disease. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.\n\ncixutumumab: Given IV\n\nlaboratory biomarker analysis: Correlative studies","id":"OG005","title":"Grp 6 - Neuroblastoma-MIBG Positive Without Measurable Disease"},{"description":"Group 7 - Recurrent or Refractory Neuroblastoma -With Measurable Disease. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.\n\ncixutumumab: Given IV\n\nlaboratory biomarker analysis: Correlative studies","id":"OG006","title":"Grp 7-Neuroblastoma With Measurable Disease"},{"description":"Group 8 - Recurrent Osteosarcoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.\n\ncixutumumab: Given IV\n\nlaboratory biomarker analysis: Correlative studies","id":"OG007","title":"Group 8 - Recurrent Osteosarcoma"},{"description":"Group 9 - Recurrent or Refractory Wilms Tumor. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.\n\ncixutumumab: Given IV\n\nlaboratory biomarker analysis: Correlative studies","id":"OG008","title":"Group 9 - Recurrent or Refractory Wilms Tumor"},{"description":"Group 10 - Recurrent or Refractory Retinoblastoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.\n\ncixutumumab: Given IV\n\nlaboratory biomarker analysis: Correlative studies","id":"OG009","title":"Group 10 - Recurrent or Refractory Retinoblastoma"}],"paramType":"NUMBER","populationDescription":"Grp 2, 12 enrolled 1 ineligible, 1 progressive disease prior to first dose of therapy. Grp 3, 21 enrolled, 1 ineligible. Grp 5, 14 enrolled, 1 ineligible. Grp 8, 10 enrolled, 1 not evaluable (patient didn't receive any drug).","reportingStatus":"POSTED","timeFrame":"First six treatment cycles - 24 weeks","title":"Disease Response","type":"PRIMARY","unitOfMeasure":"patient"}